Leptin modulates electrophysiological characteristics and isoproterenol-induced arrhythmogenesis in atrial myocytes

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Lin, Yung Kuo ^a,b   Chen, Yao Chang ^c   Huang, Jen Hung ^a   Lin, Yenn Jiang ^d   Huang, Shiang Suo ^e,f   Chen, Shih Ann ^d   Chen, Yi Jen ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adipokines; Atrial fibrillation; Epicardial fat; Leptin; Obesity

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM ION; INDO 1; ISOPRENALINE; LEPTIN; POTASSIUM; SODIUM CALCIUM EXCHANGE PROTEIN;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; CALCIUM CELL LEVEL; CELL STRUCTURE; CONTROLLED STUDY; EXPERIMENTAL RABBIT; FLUORESCENCE; HEART ATRIUM FIBRILLATION; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART LEFT ATRIUM; HEART MUSCLE CELL; HEART REPOLARIZATION; ION CURRENT; MALE; MEMBRANE CURRENT; MEMBRANE STEADY POTENTIAL; MYOELECTRICITY; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SODIUM CURRENT; WHOLE CELL PATCH CLAMP; ANIMAL; CYTOLOGY; DRUG EFFECT; HEART ATRIUM; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT;

ORYCTOLAGUS CUNICULUS;

ACTION POTENTIALS; ANIMALS; ATRIAL FIBRILLATION; HEART ATRIA; LEPTIN; MALE; MYOCYTES, CARDIAC; OBESITY; RABBITS;

EID: 84890463617     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-94     Document Type: Article

References (48)

1. Obesity and the risk of new-onset atrial fibrillation. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ, JAMA 2004 292 2471 2477 (Pubitemid 39552671)
2. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, Seward JB, Gersh BJ, Eur Heart J 2008 29 2227 2233
3. Risk of new-onset atrial fibrillation in relation to body mass index. Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, Smith NL, Heckbert SR, Arch Int Med 2006 166 2322 2328 (Pubitemid 44833356)
4. Atrial fibrillation and obesity-results of a meta-analysis. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS, Am Heart J 2008 155 310 315
5. Atrial fibrillation: An old disease, a new epidemic. Tsang TS, Gersh BJ, Am J Med 2002 113 432 435 (Pubitemid 35223616)
6. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Hubert HB, Feinleib M, McNamara PM, Castelli WP, Circulation 1983 67 968 977 (Pubitemid 13080473)
7. Obesity and the risk of heart failure. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS, N Engl J Med 2002 347 305 313 (Pubitemid 34815352)
8. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15,000 middle aged men and women (the Renfrew-Paisley study). Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ, Eur Heart J 2006 27 96 106 (Pubitemid 41785938)
9. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y, Circulation 2008 117 10 1255 1260 (Pubitemid 351365676)
10. Potential atrial arrhythmogenicity of adipocytes: implications for the genesis of atrial fibrillation. Lin YK, Chen YJ, Chen SA, Med Hypotheses 2010 74 1026 1029
11. Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation. Lin YK, Chen YC, Chen JH, Chen SA, Chen YJ, Basic Res Cardiol 2012 107 5 293
12. Heart failure epicardial fat increases atrial arrhythmogenesis. Lin YK, Chen YC, Chang SL, Lin YJ, Chen JH, Yeh YH, Chen SA, Chen YJ, Int J Cardiol 2013 167 5 1979 1983
13. Leptin: a review of its peripheral actions and interactions. Margetic S, Gazzola C, Pegg GG, Hill RA, Int J Obes Relat Metab Disord 2002 26 1407 1433 (Pubitemid 36007818)
14. Lipotoxic diseases. Unger RH, Annu Rev Med 2002 53 319 336 (Pubitemid 34177884)
15. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1. Rajapurohitam V, Javadov S, Purdham DM, Kirshenbaum LA, Karmazyn M, J Mol Cell Cardiol 2006 41 2 265 274 (Pubitemid 44080214)
16. Rat heart is a site of leptin production and action. Purdham DM, Zou MX, Rajapurohitam V, Karmazyn M, Am J Physiol Heart Circ Physiol 2004 287 6 2877 H2884
17. Development of radioimmunoassay for human leptin. Hosoda K, Masuzaki H, Ogawa Y, Miyawaki T, Hiraoka J, Hanaoka I, Yasuno A, Nomura T, Fujisawa Y, Yoshimasa Y, Nishi S, Yamori Y, Nakao K, Biochem Biophys Res Commun 1996 16 234 239 (Pubitemid 26141412)
18. Effects of gender, body composition, and menopause on plasma concentrations of leptin. Rosenbaum M, Nicolson M, Hirsch J, Heymsfield SB, Gallagher D, Chu F, Leibel RL, J Clin Endocrinol Metab 1996 81 3424 3427 (Pubitemid 26296228)
19. High plasma immunoreactive leptin level in essential hypertension. Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, Shimamoto K, Am J Hypertens 1997 10 1171 1174 (Pubitemid 27486351)
20. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N, Circulation 2001 104 25 3052 3056 (Pubitemid 34014056)
21. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Schulze PC, Kratzsch J, Linke A, Schoene N, Adams V, Gielen S, Erbs S, Moebius-Winkler S, Schuler G, Eur J Heart Fail 2003 5 1 33 40 (Pubitemid 36205542)
22. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Couillard C, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ, Després JP, Diabetes Care 1998 21 782 786 (Pubitemid 28487071)
23. Leptin promotes vascular remodeling and neointimal growth in mice. Schafer K, Halle M, Goeschen C, Dellas C, Pynn M, Loskutoff DJ, Konstantinides S, Arterioscler Thromb Vasc Biol 2004 24 112 117 (Pubitemid 38082420)
24. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Rajapurohitam V, Gan XT, Kirshenbaum LA, Karmazyn M, Circ Res 2003 93 277 279 (Pubitemid 37048239)
25. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM, Circulation 2003 108 754 759 (Pubitemid 36999263)
26. From fat fighter to risk factor: the zigzag trek of leptin. Werner N, Nickenig G, Arterioscler Thromb Vasc Biol 2004 24 7 9 (Pubitemid 38082404)
27. Biological action of leptin as an angiogenic factor. Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeña G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR, Science 1998 281 1683 1686 (Pubitemid 28435586)
28. Leptin: a novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. Sader S, Nian M, Liu P, Circulation 2003 108 6 644 646 (Pubitemid 36999243)
29. Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Fukui A, Takahashi N, Nakada C, Masaki T, Kume O, Shinohara T, Teshima Y, Hara M, Saikawa T, Circ Arrhythm Electrophysiol 2013 6 2 402 409
30. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, Ren J, Hypertension 2000 36 501 505
31. Discrepant electrophysiological characteristics and calcium homeostasis of left atrial anterior and posterior myocytes. Suenari K, Chen YC, Kao YH, Cheng CC, Lin YK, Chen YJ, Chen SA, Basic Res Cardiol 2011 106 1 65 74
32. Amyloid peptide regulates calcium homoeostasis and arrhythmogenesis in pulmonary vein cardiomyocytes. Tsao HM, Weerateerangkul P, Chen YC, Kao YH, Lin YK, Huang JH, Chen SA, Chen YJ, Eur J Clin Invest 2012 42 6 589 598
33. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Balistreri CR, Caruso C, Candore G, Mediators Inflamm 2010 2010 802078
34. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Hondeghem LM, Carlsson L, Duker G, Circulation 2001 103 2004 2013 (Pubitemid 32322230)
35. Electrophysiology of single cardiomyocytes isolated from rabbit pulmonary veins: implication in initiation of focal atrial fibrillation. Chen YJ, Chen SA, Chen YC, Yeh HI, Chang MS, Lin CI, Basic Res Cardiol 2002 97 1 26 34
36. Adrenergic modulation of ultrarapid delayed rectifier K + current in human atrial myocytes. Li GR, Feng J, Wang Z, Fermini B, Nattel S, Circ Res 1996 78 5 903 915 (Pubitemid 26131375)
37. Adrenergic modulation of potassium currents in isolated human atrial myocytes. Su MJ, Chi JF, Chu SH, J Biomed Sci 1994 1 3 193 200
38. Leptin and atherosclerosis. Beltowski J, Atherosclerosis 2006 189 1 47 60 (Pubitemid 44441296)
39. Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na + and K + channels. Clancy CE, Kass RS, Physiol Rev 2005 85 1 33 47 (Pubitemid 40171257)
40. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Belardinelli L, Shryock JC, Fraser H, Heart 2006 92 v6 iv14
41. Effects of a Na+/Ca2+ exchanger inhibitor on pulmonary vein electrical activity and ouabain-induced arrhythmogenicity. Wongcharoen W, Chen YC, Chen YJ, Chang CM, Yeh HI, Lin CI, Chen SA, Cardiovasc Res 2006 70 3 497 508
42. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Fruhbeck G, Diabetes 1999 48 903 908 (Pubitemid 29153093)
43. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Wettwer E, Hála O, Christ T, Heubach JF, Dobrev D, Knaut M, Varró A, Ravens U, Circulation 2004 110 16 2299 2306 (Pubitemid 39407330)
44. Prolonged leptin treatment increases transient outward K+ current via upregulation of Kv4.2 and Kv4.3 channel subunits in adult rat ventricular myocytes. Gómez-Hurtado N, Fernández-Velasco M, Fernández-Alfonso MS, Boscá L, Delgado C, Pflugers Arch 2013 in press, doi:10.1007/s00424-013-1348-3
45. Impact of obesity and leptin treatment on adipocyte gene expression in Psammomys obesus. Sanigorski A, Cameron-Smith D, Lewandowski P, Walder K, de Silva A, Morton G, Collier GR, J Endocrinol 2000 164 1 45 50 (Pubitemid 30044328)
46. Systemic leptin administration in supraphysiological doses maintains bone mineral density and mechanical strength despite significant weight loss. Stunes AK, Westbroek I, Gordeladze JO, Gustafsson BI, Reseland JE, Syversen U, Endocrinology 2012 153 5 2245 2253
47. Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Smith CC, Dixon RA, Wynne AM, Theodorou L, Ong SG, Subrayan S, Davidson SM, Hausenloy DJ, Yellon DM, Am J Physiol Heart Circ Physiol 2010 299 4 1265 H1270
48. Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of Jak/STAT pathway. Wold LE, Relling DP, Duan J, Norby FL, Ren J, Hypertension 2002 39 1 69 74 (Pubitemid 34098091)